<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T04:21:27Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6056113" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6056113</identifier>
        <datestamp>2018-08-01</datestamp>
        <setSpec>eid</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="brief-report">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
              <journal-id journal-id-type="iso-abbrev">Emerg Infect Dis</journal-id>
              <journal-id journal-id-type="publisher-id">EID</journal-id>
              <journal-title-group>
                <journal-title>Emerging Infectious Diseases</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1080-6040</issn>
              <issn pub-type="epub">1080-6059</issn>
              <publisher>
                <publisher-name>Centers for Disease Control and Prevention</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6056113</article-id>
              <article-id pub-id-type="pmcid">PMC6056113</article-id>
              <article-id pub-id-type="pmc-uid">6056113</article-id>
              <article-id pub-id-type="pmid">29798745</article-id>
              <article-id pub-id-type="pmid">29798745</article-id>
              <article-id pub-id-type="publisher-id">17-0768</article-id>
              <article-id pub-id-type="doi">10.3201/eid2408.170768</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Dispatch</subject>
                </subj-group>
                <subj-group subj-group-type="article-type">
                  <subject>Dispatch</subject>
                </subj-group>
                <subj-group subj-group-type="TOC-title">
                  <subject>Therapeutic and Transmission-Blocking Efficacy of Dihydroartemisinin/Piperaquine and Chloroquine against <italic>Plasmodium vivax</italic> Malaria, Cambodia</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Therapeutic and Transmission-Blocking  Efficacy of Dihydroartemisinin/Piperaquine and Chloroquine against <italic>Plasmodium vivax</italic> Malaria, Cambodia</article-title>
                <alt-title alt-title-type="running-head"><italic>Plasmodium vivax</italic> Malaria, Cambodia</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Popovici</surname>
                    <given-names>Jean</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Vantaux</surname>
                    <given-names>Amelie</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Primault</surname>
                    <given-names>Lyse</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Samreth</surname>
                    <given-names>Reingsey</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Piv</surname>
                    <given-names>Eak Por</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bin</surname>
                    <given-names>Sophalai</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kim</surname>
                    <given-names>Saorin</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lek</surname>
                    <given-names>Dysoley</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Serre</surname>
                    <given-names>David</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Menard</surname>
                    <given-names>Didier</given-names>
                  </name>
                </contrib>
                <aff id="aff1">Institut Pasteur, Phnom Penh, Cambodia (J. Popovici, A. Vantaux, L. Primault, R. Samreth, E.P. Piv, S. Bin, S. Kim, D. Menard); </aff>
                <aff id="aff2">National Center for Malaria Control, Phnom Penh (D. Lek); </aff>
                <aff id="aff3">University of Maryland School of Medicine, Baltimore, Maryland, USA (D. Serre); </aff>
                <aff id="aff4">Institut Pasteur, Paris, France (D. Menard)</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">Address for correspondence: Didier Menard, Malaria Genetics and Resistance Group, Institut Pasteur, 25–28 Rue du Dr. Roux, 75724 Paris CEDEX 15, France; email: <email xlink:href="dmenard@pasteur.fr">dmenard@pasteur.fr</email></corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>8</month>
                <year>2018</year>
              </pub-date>
              <volume>24</volume>
              <issue>8</issue>
              <fpage>1516</fpage>
              <lpage>1519</lpage>
              <permissions>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.</license-p>
                </license>
              </permissions>
              <abstract>
                <p>We assessed the efficacy of standard 3-day courses of chloroquine and dihydroartemisinin/piperaquine against <italic>Plasmodium vivax</italic> malaria. Compared with chloroquine, dihydroartemisinin/piperaquine was faster in clearing asexual <italic>P. vivax</italic> parasites and blocking human-to-mosquito transmission. This drug combination was also more effective in preventing potential recurrences for <underline>&gt;</underline>2 months.</p>
              </abstract>
              <kwd-group kwd-group-type="author">
                <title>Keywords: </title>
                <kwd>malaria</kwd>
                <kwd>Plasmodium vivax</kwd>
                <kwd>parasites</kwd>
                <kwd>chloroquine</kwd>
                <kwd>dihydroartemisinin/piperaquine</kwd>
                <kwd>DHA/PPQ</kwd>
                <kwd>therapeutic efficacy</kwd>
                <kwd>transmission-blocking efficacy</kwd>
                <kwd>efficacy</kwd>
                <kwd>transmission</kwd>
                <kwd>Anopheles dirus</kwd>
                <kwd>mosquitoes</kwd>
                <kwd>infectivity</kwd>
                <kwd>feeding assays</kwd>
                <kwd>Cambodia</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <p><italic>Plasmodium vivax</italic> is the most widespread human malaria parasite. Almost 2.5 billion persons are at risk for infection in &gt;90 countries (<xref rid="R1" ref-type="bibr"><italic>1</italic></xref>,<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>). Since the 1950s–1960s, Southeast Asia has been the cradle of emergence and spread of <italic>P. falciparum</italic> antimalarial drug resistance, a major obstacle for malaria control. Over the past decade, control efforts in Cambodia have led to an impressive decrease in malaria burden, with a slower decrease of <italic>P. vivax</italic> than for <italic>P. falciparum</italic> (<xref rid="R3" ref-type="bibr"><italic>3</italic></xref>).</p>
            <p><italic>P. vivax</italic> resistance to chloroquine has emerged more recently; the first cases were observed in 2009 in Rattanakiri Province in northeastern Cambodia (17.4% treatment failures after 28 days of follow-up), which led to withdrawal of chloroquine and use of dihydroartemisinin/piperaquine (DHA/PPQ) as first-line therapy for uncomplicated <italic>P. vivax</italic> malaria in 2012 (<xref rid="R4" ref-type="bibr"><italic>4</italic></xref>). We assessed the efficacy of standard 3-day courses of chloroquine and DHA/PPQ for treating <italic>P. vivax</italic> malaria, preventing recurrences, and blocking human-to-mosquito transmission.</p>
            <sec sec-type="other1">
              <title>The Study</title>
              <p>We conducted an open-label, randomized, control trial in June–December 2014 in Rattanakiri Province, Cambodia. Febrile patients or patients with a history of fever in the previous 48 h who sought treatment in health facilities and had positive results by rapid diagnostic test (CareStart Malaria HRP2/pLDH Pf/PAN Combo; Access Bio, Inc., Somerset, NJ, USA) for non–<italic>P. falciparum</italic> malaria were offered participation in the study. Pregnant or lactating women and patients with signs of severe malaria, other known illnesses, or inability to provide informed consent were excluded. Patients with <italic>P. vivax</italic> monoinfection confirmed by PCR were eligible for the study (<xref rid="R5" ref-type="bibr"><italic>5</italic></xref>). </p>
              <p>At enrollment, after we obtained written informed consent, patients were randomized to receive supervised standard 3-day courses of DHA/PPQ (Duo-Cotecxin; Zhejiang Holley Nanhu Pharmaceutical Co., Ltd., Jiaxing, China) or chloroquine (Nivaquine; Sanofi-Aventis, Paris, France). For each participant, medical histories were obtained and clinical and biological examinations performed. We followed up with patients according to an extended World Health Organization protocol on days 1, 2, 3, 5, and 7 and then weekly until day 63. At each visit, we performed clinical examinations and obtained an axillary temperature and a capillary blood sample. </p>
              <p>Malaria parasites were detected by microscopy (Giemsa-stained blood films) and PCR as described (<xref rid="R5" ref-type="bibr"><italic>5</italic></xref>). Chloroquine resistance was ruled out for patients if no parasites were detected by microscopy on day 28 or, in case of recurrence, if the chloroquine blood concentration on the day of recurrence did not exceed &gt;100 ng/mL (<xref rid="R6" ref-type="bibr"><italic>6</italic></xref><italic>,</italic><xref rid="R7" ref-type="bibr"><italic>7</italic></xref>). We measured chloroquine blood concentrations by using liquid chromatography–tandem mass spectrometry for 50-μL samples of whole blood.</p>
              <p>During January–March 2016, we conducted an additional study at the same site to evaluate the infectivity of <italic>P. vivax</italic> from blood of symptomatic patients to <italic>Anopheles dirus</italic> mosquito vectors; we tested pretreatment and posttreatment blood samples by using membrane feeding assays without serum replacement (<xref rid="R8" ref-type="bibr"><italic>8</italic></xref>). Any febrile patients seeking antimalarial treatment with similar inclusion/exclusion criteria described previously were enrolled in this study.</p>
              <p>After we obtained written informed consent, we fed batches of 50 <italic>An. dirus</italic> mosquitoes with blood collected from these patients on 3 occasions: 1) before the first dose of DHA/PPQ or chloroquine, 2) on the same day at 9:00 <sc>pm</sc> (i.e., 2–11 h after treatment), and 3) at 24h posttreatment for patients treated with chloroquine. We performed statistical analyses by using GraphPad Prism 5 (GraphPad, San Diego, CA, USA) and R software (<xref rid="R9" ref-type="bibr"><italic>9</italic></xref>). Both studies were approved by the Cambodian National Ethic Committee (038 NECHR, 2/24/2014 and 475 NECHR, 12/28/2015).</p>
              <p>For the drug comparison study, we enrolled 50 patients (25 in each study arm); in each arm, 5 patients were lost to follow-up during days 2–35. A total of 40 patients (20 in each study arm) were followed up until day 63. Baseline patient characteristics were similar for both patient groups (<xref rid="T1" ref-type="table">Table 1</xref>). We did not observe any adverse events or early clinical failures. The proportion of patients still parasitemic on days 1 and 2 (detected by microscopy) was lower for the DHA/PPQ–treated group than for the chloroquine-treated group (<xref rid="T2" ref-type="table">Table 2</xref>). Medians of the parasite reduction ratio recorded on days 1 and 2 were higher for the DHA/PPQ–treated patient group (<xref rid="T2" ref-type="table">Table 2</xref>). All patients, regardless of their treatment, were microscopically parasite free at day 3.</p>
              <table-wrap position="float" id="T1">
                <label>Table 1</label>
                <caption>
                  <title>Baseline characteristics of <italic>Plasmodium vivax</italic>–infected patients in a clinical drug trial and a human-to-mosquito transmission study, Cambodia*</title>
                </caption>
                <table frame="hsides" rules="groups">
                  <col width="252" span="1"/>
                  <col width="103" span="1"/>
                  <col width="90" span="1"/>
                  <col width="36" span="1"/>
                  <thead>
                    <tr>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Characteristic</th>
                      <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Chloroquine</th>
                      <th valign="top" align="center" scope="col" rowspan="1" colspan="1">DHA/PPQ </th>
                      <th valign="top" align="center" scope="col" rowspan="1" colspan="1">p value</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Clinical drug trial study, June–December 2014</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. patients followed up until day 63 (% Male)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">20 (80)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">20 (80)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.00†</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Patient age, y</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">26.5 (18.5–35)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">28.5 (21.5–46)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.11‡</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Patient weight, kg</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">56.0 (50–59)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">51.0 (49.5–53)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.14‡</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Parasites/μL of blood</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5,000 (1,850–8,350)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">8,900 (3,500–17,500)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.051‡</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Gametocytes/µL of blood</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">108 (58–200)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">245 (105–745)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.12‡</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Proportion with G6PD deficiency by spot test and PCR§</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2/20 (Viangchan variant)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1/20 (Canton variant)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.00†</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Leukocytes, ×10<sup>9 </sup>cells/L</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">7.7 (6.2–9.2)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6.9 (5.2–8.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.38‡</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Erythrocytes, ×10<sup>12 </sup>cells/L</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5.01 (4.53–5.26)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5.10 (4.69–5.65)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.42‡</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hemoglobin, g/dL</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">11.2 (10.3–13.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">12.3 (11.4–13.1)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.43‡</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hematocrit, %<hr/></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">37 (34–43)<hr/></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">40 (37–43)<hr/></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.49‡<hr/></td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Human-to-mosquito transmission study, January–March 2016¶</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. (%) male patients</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">9 (100)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">10 (70)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.21†</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Patient age, y</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">13.0 (12.7–38.5)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">24.5 (19.0–29.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.68‡</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Patient weight, kg</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">37.0 (28.7–52.2)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">53.5 (42.0–60.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.09‡</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Parasites/μL of blood</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4,565 (3,462–6,184)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">9,069 (6,833–11,591)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>0.01‡</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Gametocytes/μL of blood</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">221 (74.2–381.5)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1,915 (693–2,729)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>0.001‡</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Proportion of infectious patients before treatment; feeding assay   before first dose of treatment#</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">8/9 (89)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">9/10 (90)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.00†</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Proportion of infected mosquitoes before treatment; feeding assay   before first dose of treatment</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">69.6 (26.2–84.9)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">72.9 (29.75–92.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.71‡</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Average no. oocysts in infected mosquitoes before treatment;   feeding assay before first dose of treatment</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">12.2 (2.4–29.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">12.2 (2.4–40.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.74‡</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p>*Values are median (IQR) or no. positive/no. tested (%) unless otherwise indicated. Bold indicates statistical significance (p&lt;0.05). DHA/PPQ, dihydroartemisinin/piperaquine; G6PD, glucose-6-phosphate dehydrogenase; IQR, interquartile range. †By Ficher exact test. ‡By Mann-Whitney U test.  §For details, see Khim et al. (<italic>10</italic>). ¶Mosquitoes were 6–8 days old and were allowed to feed for 20 min. Feeding was conducted at the same place immediately after obtaining blood from patients. Dissections were performed 6 days after the blood meal. Midguts were dissected in 1% mercurochrome stain, and the presence and number of oocysts were determined by microscopy (×20 magnification). #Patients were defined as being infectious when <underline>&gt;</underline>1 mosquito became infected with oocysts.</p>
                </table-wrap-foot>
              </table-wrap>
              <table-wrap position="float" id="T2">
                <label>Table 2</label>
                <caption>
                  <title><italic>Plasmodium vivax</italic> clearance among infected patients, time to malaria recurrence, and vector transmission results, by allocated antimalarial drug treatment, Cambodia*</title>
                </caption>
                <table frame="hsides" rules="groups">
                  <col width="297" span="1"/>
                  <col width="76" span="1"/>
                  <col width="63" span="1"/>
                  <col width="45" span="1"/>
                  <thead>
                    <tr>
                      <th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Characteristic</th>
                      <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Chloroquine</th>
                      <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">DHA/PPQ</th>
                      <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">p value</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Clinical drug trial study, June–December 2014</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Proportion of patients parasitemic at day 1 by microscopy</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">17/20 (85)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6/20 (30)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>0.001†</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Parasites/μL of blood at day 1</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">180 (80–600)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0–57)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>0.0002‡</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Parasite reduction ratio at day</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">96.2 (68.5–98.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">100 (99.4–100)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>0.0002‡</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Proportion of patients parasitemic at day 2 by microscopy</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5/20 (25)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0/20 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>0.047†</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Parasites/μL of blood at day 2</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0–15)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>0.03‡</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Parasite reduction ratio at day 2</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">100 (99.8–100)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">100</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>0.03‡</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Proportion of patients parasitemic at day 3 by microscopy</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0/20 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0/20 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.00†</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Proportion of patients with recurrence detected by PCR</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">12/20 (60)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4/20 (20)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>0.02†</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Time to recurrence, d<hr/></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">49 (42–49)<hr/></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">56 (52.5–56)<hr/></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>0.04‡</bold>
                        <hr/>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Human-to-mosquito transmission study, January–March 2016</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Proportion of infectious patients after first dose of treatment; feeding assay   at 9:00 <sc>pm</sc></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">8/9 (89)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1/10 (10)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>0.001†</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Proportion of infected mosquitoes after first dose of treatment; feeding assay   at 9:00 <sc>pm</sc></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">60.7 (23.7–78.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>0.004‡</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Average no. of oocysts in infected mosquitoes after first dose of treatment;   feeding assay at 9:00 <sc>pm</sc></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">9.9 (4.1–25.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">356.4</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.22‡</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Parasite transmissibility reduction ratio (%) at 9:00 <sc>pm</sc></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">19 (−13.8 to 62.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">100</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>0.003‡</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Proportion of infectious patient 24 h after first dose of chloroquine</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2/9 (22)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Average no. of oocysts in infected mosquitoes after first dose of treatment for   2 infectious patients; feeding assay 24 h after first dose of chloroquine</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.3 and 2.4</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Proportion of infected mosquitoes 24 h after first dose of chloroquine</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0–4.4)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p>*Values are no. positive/no. tested (%) or median (IQR) unless otherwise indicated. Bold indicates statistical significance (p&lt;0.05). DHA/PPQ, dihydroartemisinin/piperaquine; IQR, interquartile range; ND, no data. †By Fisher exact test. ‡By Mann-Whitney U test.</p>
                </table-wrap-foot>
              </table-wrap>
              <p>Within 2 months of follow-up, there were fewer patients with a recurrence (detected by PCR) in the DHA/PPQ-treated group than in the chloroquine-treated group (odds ratio 0.17, 95% CI 0.05–0.66; p&lt;0.05, by log-rank test, p&lt;0.01 by Kaplan-Meier survival analysis) (<xref rid="T2" ref-type="table">Table 2</xref>; <xref rid="F1" ref-type="fig">Figure 1</xref>). Median time to recurrence after treatments was also delayed in patients given DHA/PPQ (56 days) compared with those patients given chloroquine (49 days) (<xref rid="T2" ref-type="table">Table 2</xref>). No recurrence occurred before day 28 in either study arm, which is suggestive of relapse or reinfection, rather than recrudescence of drug-resistant parasites (<xref rid="R6" ref-type="bibr"><italic>6</italic></xref><italic>,</italic><xref rid="R7" ref-type="bibr"><italic>7</italic></xref>). In the chloroquine-treated group, 12/20 patients with recurrence had a chloroquine blood concentration &lt;100 ng/mL on the day of recurrence (chloroquine + desethyl chloroquine: median 55.6 ng/mL, interquartile range 40.0–61.7 ng/mL); these results excluded likely chloroquine resistance (<xref rid="R6" ref-type="bibr"><italic>6</italic></xref><italic>,</italic><xref rid="R7" ref-type="bibr"><italic>7</italic></xref>).</p>
              <fig position="float" id="F1" fig-type="figure">
                <label>Figure 1</label>
                <caption>
                  <p>Cumulative proportion of patients with nonrecurrent <italic>Plasmodium vivax</italic> malaria given a 3-day course of DHA/PPQ and chloroquine detected by PCR within 63 days of follow up, Cambodia. *p&lt;0.01, by log-rank test during Kaplan-Meier survival analysis. DHA/PPQ, dihydroartemisinin/piperaquine.</p>
                </caption>
                <graphic xlink:href="17-0768-F1" position="float"/>
              </fig>
              <p>For the mosquito-to-human transmission study, we enrolled 19 patients (9 given chloroquine and 10 given DHA/PPQ). Baseline patient characteristics were similar in both patient groups, except for day 0 parasitemia and gametocytemia, which were higher for the DHA/PPQ-treated group (<xref rid="T1" ref-type="table">Table 1</xref>). The proportion of infectious blood from <italic>P. vivax</italic>–infected patients and the median proportion of infected mosquitoes fed on blood collected before the first dose of DHA/PPQ or chloroquine were similar for both patient groups (<xref rid="T1" ref-type="table">Table 1</xref>). Despite an initial higher day 0 gametocytemia for the DHA/PPQ-treated group, the proportions of infectious <italic>P. vivax</italic> blood collected at 9:00 <sc>pm</sc> after the first dose of DHA/PPQ or chloroquine and the median proportion of infected mosquitoes were lower for the DHA/PPQ-treated group than for the chloroquine-treated group (<xref rid="T2" ref-type="table">Table 2</xref>). Overall, DHA/PPQ acted faster than chloroquine in decreasing over time the proportion of infectious patients (generalized linear mixed model time for drug interaction, χ<sub>1</sub><sup>2</sup> = 113.1, p&lt; 0.0001) (<xref rid="F2" ref-type="fig">Figure 2</xref>). For the group given chloroquine, 2 (22%) of 9 blood samples were still infectious 24 hours after the first dose (<xref rid="T2" ref-type="table">Table 2</xref>).</p>
              <fig position="float" id="F2" fig-type="figure">
                <label>Figure 2</label>
                <caption>
                  <p>Transmission-blocking efficacy of allocated antimalarial drug treatment (chloroquine and DHA/PPQ) on human-to-mosquito transmission of <italic>Plasmodium vivax</italic>, January–March 2016, Cambodia. Each dot represents the parasite transmissibility reduction ratio (i.e., 100 – [proportion of infected mosquitoes fed with blood samples collected at 9:00 <sc>pm</sc> after the first dose of treatment × 100/proportion of infected mosquitoes fed with blood samples collected at patient enrollment before the first dose of treatment]). Only data of infectious patients at enrollment are shown (17/19 patients; <xref rid="T1" ref-type="table">Table 1</xref>). For the chloroquine-treated patient group, a second mosquito blood feeding was performed 24 h after the first dose. DHA/PPQ, dihydroartemisinin/piperaquine.</p>
                </caption>
                <graphic xlink:href="17-0768-F2" position="float"/>
              </fig>
            </sec>
            <sec sec-type="conclusions">
              <title>Conclusions</title>
              <p>We confirm that DHA/PPQ acts faster (<underline>&lt;</underline>48 h) than chloroquine (≈72 h) in eliminating sexual and asexual <italic>P. vivax</italic> parasites and that DHA/PPQ provides an excellent postexposure prophylaxis against potential recurrences for <underline>&gt;</underline>2 months (<xref rid="R11" ref-type="bibr"><italic>11</italic></xref>). This benefit relies on the combination of artemisinin derivatives (DHA), which are fast-acting drugs capable of eliminating any <italic>P. vivax</italic> blood stages, and a long-lasting partner drug (PPQ), which has a long terminal elimination half-life and is highly effective in preventing <italic>P. vivax</italic> recurrence for up to 56 days. Although the number of patients enrolled was small, we demonstrated that DHA/PPQ also acts faster (&lt;5 h) than chloroquine in killing <italic>P. vivax</italic> sexual stages and thus prevents the risk for transmission of parasites to the mosquito vector the night after uptake of the first dose. This rapid clearance of gametocytes is a major benefit of DHA/PPQ in comparison with chloroquine, given that <italic>P. vivax</italic> gametocytes appear early in the course of disease and must be eliminated as soon as possible to limit risk of transmission (<xref rid="R12" ref-type="bibr"><italic>12</italic></xref><italic>,</italic><xref rid="R13" ref-type="bibr"><italic>13</italic></xref>).</p>
              <p>In summary, our findings support the recommendation of DHA/PPQ as first-line treatment for <italic>P. falciparum</italic> and <italic>P. vivax</italic> uncomplicated malaria in regions to which these species are coendemic. These findings apply to areas in which chloroquine is still effective and no <italic>P. falciparum</italic> resistance to PPQ has been observed.</p>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgments</title>
              <p>We thank all patients for participating in this study.</p>
              <p>This study was supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grant R01 434 A103328) and the Institut Pasteur (grant PTR 2014–490). A.V. was supported by a Calmette and Yersin fellowship from the Institut Pasteur International Network.</p>
            </ack>
            <fn-group>
              <fn fn-type="citation">
                <p><italic>Suggested citation for this article</italic>: Popovici J, Vantaux A, Primault L, Samreth R, Piv EP, Sophalai B, et al. Therapeutic and transmission-blocking efficacy of dihydroartemisinin/piperaquine and chloroquine against <italic>Plasmodium vivax</italic> malaria, Cambodia. Emerg Infect Dis. 2018 Aug [<italic>date cited</italic>]. <ext-link xlink:href="https://doi.org/10.3201/eid2408.170768" ext-link-type="uri">https://doi.org/10.3201/eid2408.170768</ext-link></p>
              </fn>
            </fn-group>
            <bio id="d95e771">
              <p>Dr. Popovici is a research scientist of the Institut Pasteur, Phnom Penh, Cambodia. His primary research interests are a better understanding of <italic>P. vivax</italic> malaria and providing more adapted control solutions to policy makers.</p>
            </bio>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Battle</surname><given-names>KE</given-names></string-name>, <string-name><surname>Gething</surname><given-names>PW</given-names></string-name>, <string-name><surname>Elyazar</surname><given-names>IR</given-names></string-name>, <string-name><surname>Moyes</surname><given-names>CL</given-names></string-name>, <string-name><surname>Sinka</surname><given-names>ME</given-names></string-name>, <string-name><surname>Howes</surname><given-names>RE</given-names></string-name>, <etal>et al.</etal><article-title>The global public health significance of <italic>Plasmodium vivax.</italic></article-title><source>Adv Parasitol</source>. <year>2012</year>;<volume>80</volume>:<fpage>1</fpage>–<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-397900-1.00001-3</pub-id><?supplied-pmid 23199486?><pub-id pub-id-type="pmid">23199486</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Gething</surname><given-names>PW</given-names></string-name>, <string-name><surname>Elyazar</surname><given-names>IR</given-names></string-name>, <string-name><surname>Moyes</surname><given-names>CL</given-names></string-name>, <string-name><surname>Smith</surname><given-names>DL</given-names></string-name>, <string-name><surname>Battle</surname><given-names>KE</given-names></string-name>, <string-name><surname>Guerra</surname><given-names>CA</given-names></string-name>, <etal>et al.</etal><article-title>A long neglected world malaria map: <italic>Plasmodium vivax</italic> endemicity in 2010.</article-title><source>PLoS Negl Trop Dis</source>. <year>2012</year>;<volume>6</volume>:<fpage>e1814</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0001814</pub-id><?supplied-pmid 22970336?><pub-id pub-id-type="pmid">22970336</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Siv</surname><given-names>S</given-names></string-name>, <string-name><surname>Roca-Feltrer</surname><given-names>A</given-names></string-name>, <string-name><surname>Vinjamuri</surname><given-names>SB</given-names></string-name>, <string-name><surname>Bouth</surname><given-names>DM</given-names></string-name>, <string-name><surname>Lek</surname><given-names>D</given-names></string-name>, <string-name><surname>Rashid</surname><given-names>MA</given-names></string-name>, <etal>et al.</etal><article-title><italic>Plasmodium vivax</italic> Malaria in Cambodia.</article-title><source>Am J Trop Med Hyg</source>. <year>2016</year>;<volume>95</volume>(<issue>Suppl</issue>):<fpage>97</fpage>–<lpage>107</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.16-0208</pub-id><?supplied-pmid 27708187?><pub-id pub-id-type="pmid">27708187</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Leang</surname><given-names>R</given-names></string-name>, <string-name><surname>Barrette</surname><given-names>A</given-names></string-name>, <string-name><surname>Bouth</surname><given-names>DM</given-names></string-name>, <string-name><surname>Menard</surname><given-names>D</given-names></string-name>, <string-name><surname>Abdur</surname><given-names>R</given-names></string-name>, <string-name><surname>Duong</surname><given-names>S</given-names></string-name>, <etal>et al.</etal><article-title>Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated <italic>Plasmodium falciparum</italic> and <italic>Plasmodium vivax</italic> in Cambodia, 2008 to 2010.</article-title><source>Antimicrob Agents Chemother</source>. <year>2013</year>;<volume>57</volume>:<fpage>818</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00686-12</pub-id><?supplied-pmid 23208711?><pub-id pub-id-type="pmid">23208711</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Canier</surname><given-names>L</given-names></string-name>, <string-name><surname>Khim</surname><given-names>N</given-names></string-name>, <string-name><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name><surname>Sluydts</surname><given-names>V</given-names></string-name>, <string-name><surname>Heng</surname><given-names>S</given-names></string-name>, <string-name><surname>Dourng</surname><given-names>D</given-names></string-name>, <etal>et al.</etal><article-title>An innovative tool for moving malaria PCR detection of parasite reservoir into the field.</article-title><source>Malar J</source>. <year>2013</year>;<volume>12</volume>:<fpage>405</fpage>. <pub-id pub-id-type="doi">10.1186/1475-2875-12-405</pub-id><?supplied-pmid 24206649?><pub-id pub-id-type="pmid">24206649</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Baird</surname><given-names>JK</given-names></string-name>, <string-name><surname>Leksana</surname><given-names>B</given-names></string-name>, <string-name><surname>Masbar</surname><given-names>S</given-names></string-name>, <string-name><surname>Fryauff</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Sutanihardja</surname><given-names>MA</given-names></string-name>, <string-name><surname>Suradi</surname></string-name>, <etal>et al.</etal><article-title>Diagnosis of resistance to chloroquine by <italic>Plasmodium vivax</italic>: timing of recurrence and whole blood chloroquine levels.</article-title><source>Am J Trop Med Hyg</source>. <year>1997</year>;<volume>56</volume>:<fpage>621</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.1997.56.621</pub-id><?supplied-pmid 9230792?><pub-id pub-id-type="pmid">9230792</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7. </label>
                <mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. Methods for surveillance of antimalarial drug efficacy, <year>2009</year> [cited 2018 Mar 27]. <ext-link xlink:href="http://apps.who.int/iris/handle/10665/44048" ext-link-type="uri">http://apps.who.int/iris/handle/10665/44048</ext-link></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Bousema</surname><given-names>T</given-names></string-name>, <string-name><surname>Dinglasan</surname><given-names>RR</given-names></string-name>, <string-name><surname>Morlais</surname><given-names>I</given-names></string-name>, <string-name><surname>Gouagna</surname><given-names>LC</given-names></string-name>, <string-name><surname>van Warmerdam</surname><given-names>T</given-names></string-name>, <string-name><surname>Awono-Ambene</surname><given-names>PH</given-names></string-name>, <etal>et al.</etal><article-title>Mosquito feeding assays to determine the infectiousness of naturally infected <italic>Plasmodium falciparum</italic> gametocyte carriers.</article-title><source>PLoS One</source>. <year>2012</year>;<volume>7</volume>:<fpage>e42821</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0042821</pub-id><?supplied-pmid 22936993?><pub-id pub-id-type="pmid">22936993</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9. </label>
                <mixed-citation publication-type="book"><collab>R Development Core Team</collab>. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; <year>2013</year>.</mixed-citation>
              </ref>
              <ref id="R10">
                <label>10. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Khim</surname><given-names>N</given-names></string-name>, <string-name><surname>Benedet</surname><given-names>C</given-names></string-name>, <string-name><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name><surname>Kheng</surname><given-names>S</given-names></string-name>, <string-name><surname>Siv</surname><given-names>S</given-names></string-name>, <string-name><surname>Leang</surname><given-names>R</given-names></string-name>, <etal>et al.</etal><article-title>G6PD deficiency in <italic>Plasmodium falciparum</italic> and <italic>Plasmodium vivax</italic> malaria-infected Cambodian patients.</article-title><source>Malar J</source>. <year>2013</year>;<volume>12</volume>:<fpage>171</fpage>. <pub-id pub-id-type="doi">10.1186/1475-2875-12-171</pub-id><?supplied-pmid 23714236?><pub-id pub-id-type="pmid">23714236</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Sinclair</surname><given-names>D</given-names></string-name>, <string-name><surname>Gogtay</surname><given-names>N</given-names></string-name>, <string-name><surname>Brand</surname><given-names>F</given-names></string-name>, <string-name><surname>Olliaro</surname><given-names>P</given-names></string-name>. <article-title>Artemisinin-based combination therapy for treating uncomplicated <italic>Plasmodium vivax</italic> malaria.</article-title><source>Cochrane Database Syst Rev</source>. <year>2011</year>; (<issue>7</issue>):<fpage>CD008492</fpage>.<?supplied-pmid 21735431?><pub-id pub-id-type="pmid">21735431</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Sagara</surname><given-names>I</given-names></string-name>, <string-name><surname>Beavogui</surname><given-names>AH</given-names></string-name>, <string-name><surname>Zongo</surname><given-names>I</given-names></string-name>, <string-name><surname>Soulama</surname><given-names>I</given-names></string-name>, <string-name><surname>Borghini-Fuhrer</surname><given-names>I</given-names></string-name>, <string-name><surname>Fofana</surname><given-names>B</given-names></string-name>, <etal>et al.</etal><article-title>Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial.</article-title><source>Lancet Infect Dis</source>. <year>2016</year>;<volume>16</volume>:<fpage>189</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(15)00318-7</pub-id><?supplied-pmid 26601738?><pub-id pub-id-type="pmid">26601738</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Sawa</surname><given-names>P</given-names></string-name>, <string-name><surname>Shekalaghe</surname><given-names>SA</given-names></string-name>, <string-name><surname>Drakeley</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Sutherland</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Mweresa</surname><given-names>CK</given-names></string-name>, <string-name><surname>Baidjoe</surname><given-names>AY</given-names></string-name>, <etal>et al.</etal><article-title>Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial.</article-title><source>J Infect Dis</source>. <year>2013</year>;<volume>207</volume>:<fpage>1637</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jit077</pub-id><?supplied-pmid 23468056?><pub-id pub-id-type="pmid">23468056</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
